Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel
Open accessThe DOI matches its Crossref record.
Abstract
Glioma presents one of the most malignant brain tumors and the therapeutic effect is often limited due to the existence of brain tumor barrier. Based on interleukin-13 receptor α2 (IL-13Rα2) over-expression on glioma cell, it was demonstrated to be a potential receptor for glioma targeting. In this study, Pep-1-conjugated PEGylated nanoparticles loaded with paclitaxel (Pep-NP-PTX) were developed as a targeting drug delivery system for glioma treatment. The Pep-NP-PTX presented satisfactory size of 95.78 nm with narrow size distribution. Compared with NP-PTX, Pep-NP-PTX exhibited significantly enhanced cellular uptake in C6 cells (p < 0.001). The in vitro anti-proliferation evaluation showed that the IC 50 were 146 ng/ml and 349 ng/ml of Pep-NP-PTX and NP-PTX, respectively. The in vivo fluorescent image results indicated that Pep-NP had higher specificity and efficiency in intracranial tumor accumulation. Following intravenous administration, Pep-NP-PTX could enhance the distribution of PTX in vivo glioma section, 1.98, 1.91 and 1.53-fold over that of NP-PTX group after 0.5, 1 and 4 h, respectively. Pep-NP-PTX could improve the anti-glioma efficacy with a median survival time of 32 days, which was significantly longer than that of PTX-NP (23 days) and Taxol® (22 days). In conclusion, Pep-NP-PTX is a potential targeting drug delivery system for glioma treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance
Wu, W., Klockow, J. L., Zhang, M., Lafortune, F., Chang, E., Jin, L., Wu, Y., & Daldrup-Link, H. E. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105780 · Cited by 805
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Crossing the Blood–Brain Barrier: Recent Advances in Drug Delivery to the Brain
Patel, M. M., & Patel, B. M. (2017) · CNS Drugs · doi:10.1007/s40263-016-0405-9 · Cited by 430
“This work was further extended by developing copolymer nanoparticles conjugated with pep-1 for delivery of paclitaxel [101].”
BackgroundDrug Delivery to the Brain across the Blood–Brain Barrier Using Nanomaterials
Tsou, Y., Zhang, X., Zhu, H., Syed, S., & Xu, X. (2017) · Small · doi:10.1002/smll.201701921 · Cited by 258
Peptide-based targeted therapeutics: Focus on cancer treatment
Araste, F., Abnous, K., Hashemi, M., Taghdisi, S. M., Ramezani, M., & Alibolandi, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.11.004 · Cited by 161
Metadata
- Authors
- Wang, B., Lv, L., Wang, Z., Jiang, Y., Lv, W., Liu, X., Wang, Z., Zhao, Y., Xin, H., & Xu, Q.
- Venue
- Scientific Reports
- Published
- 2015-11-16
- Volume
- 5
- Issue
- 1
- Pages
- 16589-16589
- ISSN
- 2045-2322 (ISSN-L)
- OpenAlex
- W2416397933
- Cited by
- 63
- References
- 0
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel. https://app.cochat.ai/papers/10.1038/srep16589
- The paper
- Wang, B., Lv, L., Wang, Z., Jiang, Y., Lv, W., Liu, X., Wang, Z., Zhao, Y., Xin, H., & Xu, Q. (2015). Improved anti-glioblastoma efficacy by IL-13Rα2 mediated copolymer nanoparticles loaded with paclitaxel. Scientific Reports. https://doi.org/10.1038/srep16589
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.